Unpacking Samsung Biologics (207940) Earnings: 1Q Operating Profit Misses Estimates Despite Strong Sales and Net Profit Growth

Samsung Biologics on Smartkarma

Analyst coverage of Samsung Biologics on Smartkarma, an independent investment research network, shows positive sentiment towards the company’s recent performance and future outlook. According to Tina Banerjee‘s research reports, Samsung Biologics (207940 KS) reported a stellar performance in 4Q23 with 11% YoY revenue growth, fueled by Plant 4 operations and a strong sales backlog. The company closed 2023 with record-high revenue and operating profit, defying the weakening trend in the global CDMO sector. The outlook remains robust, with expectations of 10-15% annual revenue growth in 2024.

In another report by Tina Banerjee, Samsung Biologics impressed with better-than-expected results in 3Q23, achieving a record-high quarterly revenue of KRW1.03 trillion. With a backlog of $11.8 billion, the company aims for over 20% annual revenue growth in 2023. Samsung Biologics has secured key clients in the biopharmaceutical industry and continues to expand its operations with the upcoming completion of Plant 5 in 2025. The analyst sentiment remains bullish on Samsung Biologics, highlighting the company’s strong performance and growth prospects.

A look at Samsung Biologics Smart Scores

Smart Score is a compound score for the Company indicating its overall outlook. It is derived by taking an equally weighted average of underlying Factor scores computed by Smartkarma

Based on Smartkarma Smart Scores, Samsung Biologics is positioned for strong long-term growth and resilience in the bio-healthcare industry. With a high Growth score of 5, the company is expected to experience significant expansion and development in the coming years. Additionally, Samsung Biologics has solid scores in Resilience and Momentum, indicating its ability to withstand market challenges and maintain positive momentum in its operations.

Although Samsung Biologics receives lower scores in Value and Dividend, its overall outlook remains promising due to its exceptional potential for growth and resilience. As a manufacturer of bio-healthcare products, the company plays a crucial role in developing and distributing biopharmaceuticals, highlighting its importance in the healthcare sector.

Disclaimer: This article by Smartkarma is general in nature and based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. Note that our articles may not factor in the latest price-sensitive company announcements or qualitative material.
While all reasonable care has been taken in the preparation, Smartkarma makes no assurance about the accuracy of any generated data or content. All content is indicative only and should be independently checked for accuracy and confirmed before use. Smartkarma accepts no responsibility for any loss or damage caused as a result of any inaccuracy or error within the Lab online tools or generated data.
Have feedback on this article? Concerned about the content? Get in touch with us directly.

💡 Before it’s here, it’s on Smartkarma